Murine LL2 (lung cancer), B16F10 (melanoma), and CT26 (colon cancer) tumor cells modified to express FAP, used as a whole-tumor cell vaccine, can induce antitumor immunity against both tumor cells and CAFs, with a notable enhancement of CD8+ T lymphocytes infiltration and a decrease of immunosuppressive cell accumulation within the TME [227]. This evidence concerns the gene FAP and neoplasm.